US Genomics' New Resolution

In distancing itself from developing technology for single-molecule genome sequencing, US Genomics has partly moved from developing a potentially disruptive technology to providing incremental improvements, first in genomics research. The appeal is that the start-up can get to the market and generate product revenues faster. But whether its new focus will provide the big margins or access to big markets that venture investors find appealing remains an open question.

When Stephen DeFalco became CEO of US Genomics Inc. (USG) two and a half years ago, he took over a start-up that had overpromised on a technology and needed to retool. Since USG's formation in 1997, founder Eugene Chan had been articulating a vision of being able to read the sequence of an entire genome continuously, base pair by base pair, by feeding full-length DNA through an instrument like running film through a projector. Such a technology would be fast, accurate, and would enable the so-called $1,000 genome—the price point at which sequencing any person's genome from scratch becomes clinically feasible, according to current thinking.

But four years after founding the company, Chan's team remained dogged by a core issue facing start-ups pursuing single-molecule sequencing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.